NCT07018037Recruiting
Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
Pilot Study to Describe the Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma
Source: ClinicalTrials.gov · Last updated 5 Jun 2026
Brief summary (registry, in English)
The aim of this project is to descriptively explore the trend of torquetenovirus viral load TTV during therapy with immune checkpoint inhibitor ICI in these patients, to evaluate a possible role of this virus as a biomarker of response.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 4 Jun 2025
- Start date
- 29 Jan 2025
- Primary completion date
- 29 Jan 2026
- Lead sponsor
- Regina Elena Cancer Institute
- Diseases
- Kidney cancer
- NCT number
- NCT07018037
What you commit to
- Study type: Observational
- Planned participants: 20
- From 29 Jan 2025 to the primary completion date, 29 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous neoplasms;
- Previous antineoplastic treatments;
- Previous steroid treatments;
Other illness
- Active viral infections (e.g., HCV, HIV, etc.);
Other
- Lack of autonomy in adhering to study procedures.
Who the study is looking for
- Patients over 18 years of age;
- Histological diagnosis of clear cell renal cell carcinoma;
- Evidence of advanced or metastatic disease;
- Patients diagnosed with metastatic clear cell renal cell carcinoma about to start first-line immunotherapy (ICI + ICI or ICI + TKI);
- Patients able to comply with the study procedures.
- Patients who give written informed consent personally or through a witness (study participation and data processing), before any study-specific procedure is started.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Regina Elena National Cancer Institute Coordinator of this site? Confirm its status | Rome | Italy | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.